The two events that cause treatment failure in acute myeloid leukemia (AML) are 'early death' and, most commonly, resistance to therapy. Resistance is usually manifested as relapse after a brief period of remission and less often by failure to enter complete remission (CR) despite living long enough to not be classified as 'early death.' Although any definition of early death is somewhat arbitrary, we classify patients dying within 7 weeks of the start of chemotherapy as 'early death.' This reflects our observations that patients who achieve CR only after Ͼ7 weeks from the start of therapy have subsequent survival more like those patients who never achieve CR than patients who achieve CR within 7 weeks (see below). Thus, disease in patients who die after 7 weeks have elapsed has in fact exhibited a degree of resistance even though the marrow may remain hypocellular at death. We believe outcome in such patients should be classified as 'resistant' rather than as 'early death. ' The factors ('covariates') that predict early death differ from those that predict resistance to therapy. Factors predicting for early death are age, performance status, and organ function. Factors that predict for chemotherapy resistance are cytogenetics and a history of abnormal blood counts that antedate the diagnosis of AML by at least 1 month. An important question is, how predictive are currently known prognostic factors taken in combination, for example in 'multivariate model?' Dr Richard Simon at the National Cancer Institute explored this issue when he reviewed two papers that used multivariate analysis, and developed models to predict the probability of getting a remission or staying in remission. 1 He determined that the models accounted for about 20% of the variability in treatment outcome. The remaining 80% could represent random variation or, more hopefully, could be explained by new prognostic factors.
Two examples of new pretreatment prognostic factors are levels of expression of the MDR-1 gene and levels of cellular vascular endothelial growth factor (VEGF).
2 MDR-1 levels appear to be independent of cytogenetics in their ability to predict which patients will be resistant to induction therapy, but are less useful in predicting remission duration. Higher levels of cellular VEGF appear to be associated with shorter survival; this also appears independent of cytogenetics as well as age.
Identification of post-treatment prognostic factors would be the most useful step to improve our ability to forecast outcome. For example, the number of courses needed to achieve CR is the most powerful factor associated with remission duration, having more prognostic significance than even initial cytogenetics. We have more recently extended these observations by focusing on time to CR in patients whose response is known after the first course of therapy. Among 1101 such patients with AML and high-risk myelodysplastic syndrome (MDS), 740 went into remission, 71 were resistant, and 290 died. 3 Of the 740 who went into remission, not surprisingly, 80% subsequently died. Using a multivariate model where T C is the time from beginning of treatment to CR and T CD is the time from CR to death, the correlation coefficient between T C and T CD was negative, suggesting that the less time it took to go into remission, the longer the subsequent survival time. This conclusion remained the same after accounting for the effect of age, cytogenetics, and treatment on T CD . The only covariate significantly affecting the T C was increasing age. The median survival time was always longer in patients achieving a remission than in those who were declared resistant, confirming that achievement of a CR is a meaningful endpoint. However, the survival of patients who took Ͼ7 weeks to enter remission was similar to that of patients who were resistant. The same applied in various cytogenetic subsets, eg, inv(16) or t(8;21) and −5 or −7. We hypothesize that time to CR provides a clinical measurement of minimal residual disease.
Results of PCR testing may provide another clinically relevant, ie prognostic, post-treatment indicator of minimal residual disease. The value of PCR testing in CR in patients with acute promyelocytic leukemia is already established. It must not be assumed, however, that because a 'molecular' test indicates the presence of minimal residual disease, the test is per se prognostic. It is known, for example, that patients with t(8;21) AML may have sustained remissions despite detection of the t(8;21) by PCR in remission.
Methodological issues in evaluation of prognostic factors
In considering how methodological issues impact evaluation of prognostic factors, the following aspects must be taken into consideration: selection of cutpoints, potential interactions between factors, time dependency, and sample bias. Selection of cutpoints for variables such as white blood count can significantly impact the outcome of the analysis. One method often used to determine cutpoints is the optimal P value method. 4 Essentially, various possible cutpoints are examined and the one that gives the optimal separation between groups (ie, the cutpoint associated with the lowest P value) is selected. The problem with this method is that an adjustment factor is necessary to account for the multiple tests of significance performed, but is not always used. Such failure may explain why factors identified as prognostic in one study are not so identified in another study.
Graphical methods, eg, those employing martingale residuals, are an alternative method to cutpoint selection. 5 We used such methods, for example, to determine the relationship between how long blood counts had been abnormal before the diagnosis of AML or high-risk MDS was established (length of 'AHD') and survival. On the X-axis are plotted values for the variable in question (eg, how long, in months from 0 to 120, counts had been abnormal prior to diagnosis). On the Yaxis are plotted residuals. The line corresponding to Y = 0 is what would be expected for the population if one knew nothing at all about AHD; ie, this line represents the underlying hazard rate for the population. The residual that is plotted on the Y-axis represents how far each individual data point for a patient with AHD of length X months differs from the line Y = 0. A positive residual (Y Ͼ 0) indicates that the patient lives less long than expected knowing nothing about an effect on survival of length of AHD; a negative residual (Y Ͻ 0) indicates that the patient lives longer than expected in the absence of knowledge about an effect of AHD length. A 'smoother' connects the individual data points and one examines whether a pattern is present.
In the case of AHD, it appeared that the longer the AHD the greater the residual; residuals were negative at AHD lengths of zero and then became positive. This suggests that AHD is not an 'all-or-none' type variable (ie, having a negative effect on prognosis only if present for, say, 3 months), but rather has a continuously negative effect on prognosis, at least up to lengths of 2 years. The pattern identified graphically (eg, that AHD is continuous) is verified using a statistical test of significance. Once verified, the variable is treated using, in statistical modeling, the pattern identified graphically. Failure to do so (eg, treating AHD as a dichotomous rather than a continuous variable) violates the assumption of log linearity that underlies the commonly used Cox model. This emphasizes that it is crucial to check the assumptions underlying the model. This is done using well-described methods for 'goodness-of-fit' analysis. Failure to employ such model criticism is common and can lead to substantively misleading inferences about the effect of a putative prognostic factor. Applying similar methods to age indicates that age is also a continuous variable. Therefore, if one uses a model with arbitrary age cutoffs (eg, age Ͻ60 or Ͼ60) there is a real probability that the model will be suboptimal.
Another assumption underlying the Cox model is that the effect of a covariate remains the same throughout the course of the patient's treatment. Simple clinical observation indicates that this is unlikely to be the case. Indeed, when the effect of age as a function of time from treatment is examined using graphical methods analogous to those described above, one finds that the prognostic significance of age disappears once 1 year has elapsed from treatment date. Likewise, after about 6 weeks, the effect of performance status becomes much less significant. Cytogenetics, however, has a more significant effect as time goes on. Models must therefore be adjusted for time dependency of the variables. Again, failure to do this will result in a model that is poorly fit, with potential implications for the future validity of the model.
It is also important to test for interactions between prognostic factors. For example, in a recent analysis comparing outcome in patients given mylotarg with patients given ara-Ccontaining combinations at first relapse, we found that both length of first CR and salvage treatment given (mylotarg vs ara-C) were predictive of outcome. However, these two factors interacted such that mylotarg was superior in patients with short first CRs and ara-C was superior in patients with longer first CRs. Testing for interactions between factors such as length of first CR and treatment should be routine when doing either logistic regression or Cox regression. An alternative approach is to use classification and regression tree ('CART') methodology.
Potential sample bias, in particular when studying the prognostic significance of a new laboratory variable, should also Leukemia be mentioned. For example, we examined the prognostic significance of pretreatment plasma (as opposed to cellular) VEGF levels in patients with untreated AML. The number of patients in whom samples were obtained for measurement of plasma VEGF was only a fraction of all patients seen during the time when the VEGF analyses were being performed. We found that plasma VEGF was predictive of outcome. However, in the population in which plasma VGEF was measured, performance status and cytogenetics were not predictors even when VEGF was not included in the model. Obviously, this suggests that the patients in whom plasma VEGF was measured were a biased subset, with characteristics quite different from the general AML population, thus throwing doubt on any conclusions about the prognostic significance of plasma VEGF. As a practical matter, it is important to at least compare outcome in patients in whom a measurement was and was not performed before drawing conclusions about the prognostic significance of what was measured. Indeed, in the plasma VEGF data set, patients in whom plasma VEGF was determined had a better prognosis than those in whom plasma VEGF was not determined.
Uses of prognostic factors
Prognostic factors are of obvious importance in comparisons of patients in historically controlled studies. Analysis of prognostic factors can also be important in randomized studies enrolling less than 200 patients. This is because in studies of such size the mere act of randomization does not ensure balance between treatment arms with respect to important prognostic covariates. For example, in our randomized study of alltrans retinoic acid (ATRA), G-CSF, and chemotherapy, 6 initial analysis suggested an advantage for ATRA treatment. The relevant covariates (eg, age, cytogenetics) appeared well balanced (P values Ͼ0.05) among treatment groups (ATRA, no ATRA, etc). Yet the advantage in the ATRA group disappeared after multivariate regression. This suggests that it is not sufficient to examine balance between treatment arms with respect to important prognostic factors by merely examining the factors one by one, as is usually done. Rather, even in randomized studies, multivariate analyses should be done with the treatment arm included, along with age, cytogenetics, etc, as a possible predictor of outcome.
Another use of prognostic factors is to assign patients to treatment groups. We are currently using both age and cytogenetics. Because patients over age 65 have a 25-30% early death rate, we assign these patients, and all patients with Zubrod performance status 3-4, to therapy that might plausibly reduce the early death rate while maintaining the CR rate. Currently, we are examining mylotarg by itself, and in the future, may examine mylotarg plus bcl-2 antisense or plus arsenic or low-dose decitabine for this purpose. In contrast in younger patients, early death rates are Ͻ10%. Accordingly, in patients age Ͻ65 with Zubrod performance status 0-2, we are examining a 'double induction' approach in which patients receive a second course of chemotherapy on day 14 of course one regardless of day 14 marrow status. This approach is currently limited to patients who present with a normal karyotype. The rationale is that such patients are more likely to benefit from a dose intensification strategy, such as double induction, than younger patients with an abnormal karyotype. This is important because double induction carries an increased risk of early death; hence our desire to use it in patients relatively likely to benefit. In younger patients with an abnormal karyotype, we are focusing on new drugs. In principle, we believe it would be acceptable to abandon ara-C entirely in these patients, given the virtual incurability of such patients when given standard ara-C-containing regimens, even followed by allogeneic transplantation. In contrast, abandonment of ara-C would be more difficult to justify in younger patients with a normal karyotype because ara-C produces potential cure in perhaps 25% of such patients.
The future is likely to see the use of more sophisticated prognostic features to assign patients to therapies that specifically target particular biologic characteristics. For example, therapy-targeting angiogenesis may be most useful in patients presenting with high levels of marrow microvascular density (MVD). If so, measurement of marrow MVD might become routine. As more prognostic factors such as MVD are discovered, it is likely that there will be an increasing number of distinct subgroups of AML, each perhaps responding best to a different type of treatment. The implications of this for clinical research have received little attention. In particular, will we be satisfied with the longer time it will take to complete clinical trials consequent to the relatively small number of patients in each distinct subgroup and the continued desire to accrue a relatively large number of patients in the various subgroups? Alternatively, will we adjust our thinking so as to be satisfied with higher rates of potentially false negative and false positive results than is now considered acceptable, but rates that would allow trials to accrue fewer patients and thus be completed more rapidly.
